Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays
Abstract Traditional anticoagulant agents such as vitamin K antagonists (VKAs), unfractionated heparin (UFH), low molecular weight heparins (LMWHs) and fondaparinux have been widely used in the prevention and treatment of thromboembolic diseases. However, these agents are associated with limitations, such as the need for regular coagulation monitoring (VKAs and UFH) or a parenteral route of administration (UFH, LMWHs and fondaparinux). Several non-VKA oral anticoagulants (NOACs) are now widely used in the prevention and treatment of thromboembolic diseases and in stroke prevention in non-valvular atrial fibrillation. Unlike VKAs, NOACs exhibit predictable pharmacokinetics and pharmacodynamics. They are therefore usually given at fixed doses without routine coagulation monitoring. However, in certain patient populations or special clinical circumstances, measurement of drug exposure may be useful, such as in suspected overdose, in patients experiencing a hemorrhagic or thromboembolic event during the treatment’s period, in those with acute renal failure, in patients who require urgent surgery or in case of an invasive procedure. This article aims at providing guidance on laboratory testing of classic anticoagulants and NOACs..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Thrombosis journal - 12(2014), 1 vom: 04. Nov. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Douxfils, Jonathan [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Apixaban |
|---|
| Anmerkungen: |
© Douxfils et al.; licensee BioMed Central Ltd. 2014. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( |
|---|
| doi: |
10.1186/1477-9560-12-24 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR028868382 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR028868382 | ||
| 003 | DE-627 | ||
| 005 | 20230519071911.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/1477-9560-12-24 |2 doi | |
| 035 | |a (DE-627)SPR028868382 | ||
| 035 | |a (SPR)1477-9560-12-24-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Douxfils, Jonathan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Douxfils et al.; licensee BioMed Central Ltd. 2014. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( | ||
| 520 | |a Abstract Traditional anticoagulant agents such as vitamin K antagonists (VKAs), unfractionated heparin (UFH), low molecular weight heparins (LMWHs) and fondaparinux have been widely used in the prevention and treatment of thromboembolic diseases. However, these agents are associated with limitations, such as the need for regular coagulation monitoring (VKAs and UFH) or a parenteral route of administration (UFH, LMWHs and fondaparinux). Several non-VKA oral anticoagulants (NOACs) are now widely used in the prevention and treatment of thromboembolic diseases and in stroke prevention in non-valvular atrial fibrillation. Unlike VKAs, NOACs exhibit predictable pharmacokinetics and pharmacodynamics. They are therefore usually given at fixed doses without routine coagulation monitoring. However, in certain patient populations or special clinical circumstances, measurement of drug exposure may be useful, such as in suspected overdose, in patients experiencing a hemorrhagic or thromboembolic event during the treatment’s period, in those with acute renal failure, in patients who require urgent surgery or in case of an invasive procedure. This article aims at providing guidance on laboratory testing of classic anticoagulants and NOACs. | ||
| 650 | 4 | |a Vitamin K antagonist |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Dabigatran |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Rivaroxaban |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Apixaban |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Low molecular weight heparin |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Enoxaparin |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Monitoring |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Non-VKA oral anticoagulants |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Tamigniau, Anne |4 aut | |
| 700 | 1 | |a Chatelain, Bernard |4 aut | |
| 700 | 1 | |a Goffinet, Catherine |4 aut | |
| 700 | 1 | |a Dogné, Jean-Michel |4 aut | |
| 700 | 1 | |a Mullier, François |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Thrombosis journal |d London : Biomed Central, 2003 |g 12(2014), 1 vom: 04. Nov. |w (DE-627)SPR028865979 |w (DE-600)2118392-2 |x 1477-9560 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2014 |g number:1 |g day:04 |g month:11 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/1477-9560-12-24 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2014 |e 1 |b 04 |c 11 | ||